Published in AIDS Weekly, November 8th, 2004
The HSV2 trial, being carried out at The Centre for Clinical Studies in Houston, Texas is being conducted in 36 otherwise healthy individuals with recurrent genital herpes caused by HSV2. In addition to assessing the safety and tolerability of the vaccine, this study will also assess the immune response of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.